Stockscreener 앱 받기
2.36
0.00%
0.00
전일 마감가:
$2.36
열려 있는:
$2.37
하루 거래량:
1.24M
Relative Volume:
0.31
시가총액:
$227.19M
수익:
-
순이익/손실:
$-67.68M
주가수익비율:
-1.4217
EPS:
-1.66
순현금흐름:
$-54.24M
1주 성능:
-7.45%
1개월 성능:
-3.67%
6개월 성능:
+31.11%
1년 성능:
-19.73%
1일 변동 폭
$2.35
$2.415
1주일 범위
$2.35
$2.68
52주 변동 폭
$0.9857
$3.67
Cabaletta Bio Inc Stock (CABA) Company Profile
명칭
Cabaletta Bio Inc
전화
(267) 759-3100
주소
2929 ARCH STREET, PHILADELPHIA, PA
CABA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.36 | 227.19M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 재개 | Jefferies | Buy |
| 2024-12-20 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | 개시 | UBS | Buy |
| 2024-02-05 | 개시 | Jefferies | Buy |
| 2023-11-29 | 개시 | William Blair | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 개시 | Stifel | Buy |
| 2023-09-05 | 개시 | Citigroup | Buy |
| 2023-07-18 | 개시 | Guggenheim | Buy |
| 2023-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-06-30 | 개시 | Mizuho | Buy |
| 2021-01-08 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-13 | 개시 | H.C. Wainwright | Buy |
| 2019-11-19 | 개시 | Cowen | Outperform |
| 2019-11-19 | 개시 | Evercore ISI | Outperform |
| 2019-11-19 | 개시 | Morgan Stanley | Overweight |
모두보기
Cabaletta Bio Inc 주식(CABA)의 최신 뉴스
Cabaletta Bio, Inc. $CABA Shares Acquired by Bain Capital Life Sciences Investors LLC - MarketBeat
CABA Receives FDA Orphan Status for Myasthenia Gravis Treatment - GuruFocus
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Weekly Earnings: Will Cabaletta Bio Inc stock recover faster than marketMarket Sentiment Report & Technical Pattern Based Buy Signals - BỘ NỘI VỤ
Cabaletta Bio (CABA) Price Target Increased by 15.31% to 14.41 - Nasdaq
Cabaletta Bio (CABA) Stock Analysis Report | Financials & Insights - Benzinga
Evercore Healthcare Conference - marketscreener.com
Is Cabaletta Bio Inc stock gaining market shareWeekly Trading Summary & Low Risk High Win Rate Picks - BỘ NỘI VỤ
Cabaletta Bio Prices Public Offering to Raise $100 Million - MSN
Cabaletta Bio Advances Rese-cel Pipeline as BLA Submission for Myositis Nears - MSN
Form 8-KCurrent report - ADVFN
Jefferies Financial Group Inc. Takes $3.04 Million Position in Cabaletta Bio, Inc. $CABA - MarketBeat
Cabaletta Bio to Present at Key Global Healthcare and Immunology Conferences - MSN
How supply chain issues affect Cabaletta Bio Inc. stock2025 Winners & Losers & Comprehensive Market Scan Insights - newser.com
Can Cabaletta Bio Inc. stock maintain operating margins2025 Market Overview & Free Real-Time Volume Trigger Notifications - newser.com
Will Cabaletta Bio Inc. stock outperform Nasdaq indexQuarterly Profit Review & High Accuracy Buy Signal Tips - newser.com
How Cabaletta Bio Inc. stock reacts to oil pricesJuly 2025 Momentum & Safe Capital Growth Trade Ideas - newser.com
How Cabaletta Bio Inc. stock performs in rising dollar environmentTrade Risk Assessment & Weekly High Momentum Picks - newser.com
CABALETTA BIO INC (CABA.MX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Why Cabaletta Bio Inc. stock could rally in 2025Bond Market & AI Based Buy/Sell Signal Reports - newser.com
Cabaletta Bio’s Bold Autoimmune Push Raises Big Questions About the Future of CAR T - MyChesCo
Tools to assess Cabaletta Bio Inc.’s risk profileJuly 2025 WrapUp & Precise Entry and Exit Recommendations - newser.com
Is Cabaletta Bio Inc. stock attractive for ETFsLong Setup & Weekly Return Optimization Plans - newser.com
Will Cabaletta Bio Inc. see short term momentumLong Setup & Real-Time Stock Entry Alerts - newser.com
How Cabaletta Bio Inc. stock reacts to bond yieldsChart Signals & Verified Short-Term Plans - newser.com
Visualizing Cabaletta Bio Inc. stock with heatmapsRate Cut & Fast Entry High Yield Tips - newser.com
What technical signals suggest for Cabaletta Bio Inc. stock2025 Dividend Review & Weekly Top Gainers Alerts - newser.com
Is Cabaletta Bio Inc. stock a contrarian buy2025 Trading Volume Trends & Safe Capital Investment Plans - Fundação Cultural do Pará
Cabaletta Bio Advances in Autoimmune Therapy Development - MSN
Cabaletta Bio FY2025 EPS Estimate Increased by William Blair - MarketBeat
Advanced analytics toolkit walkthrough for Cabaletta Bio Inc.July 2025 Reactions & High Accuracy Trade Signal Alerts - newser.com
Cabaletta Bio (CABA) Gets a Buy from H.C. Wainwright - The Globe and Mail
Cabaletta Bio Draws Analyst Praise Despite Growing Losses - Finimize
Cabaletta Bio Inc (CABA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):